NCT01087151已完成2 期
A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 118
- 主要终点
- Progression-free survival
研究概览
简要总结
This Phase II, randomized, open-label, international, multicenter trial is designed to evaluate the safety and efficacy of rituximab monotherapy when given according to a dose intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when combined with dose-intense rituximab in previously untreated patients with B-cell CLL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously untreated, CD20-positive B-cell CLL
- •ECOG performance status of 0 or 1
- •Life expectancy > 6 months
- •Willingness and capability to be accessible for follow-up until study termination or death
- •For patients of reproductive potential (both males and females), use of a reliable means of contraception
排除标准
- •Prolymphocytic leukemia
- •Richter's transformation to an aggressive B-cell malignancy (e.g., DLBCL)
- •Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of progression at baseline
- •Patients with a history of other malignancies within 2 years prior to study entry except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, low-grade, localized prostate cancer treated surgically with curative intent or one that carries a good prognosis, in situ ductal carcinoma of the breast treated with lumpectomy alone with curative intent
- •Prior treatment with rituximab, ABT-263 or other pro-apoptotic agents
- •Current or recent (within the 28 days prior to initiation of study treatment) participation in another experimental drug study
- •Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury within 28 days prior to treatment onset or anticipation of the need for major surgery during the course of the study
- •Active infection requiring parenteral antibiotics or antiviral or antifungal agents at the onset of study treatment
- •Receipt of primary or booster vaccination with live-virus vaccines for up to 6 months prior to initiation of study treatment
- •Patients receiving therapeutic anticoagulation with heparin or warfarin or patients receiving any drugs or herbal supplements that are known to inhibit platelet function (including low-dose aspirin) within 7 days of the first dose of ABT-
- •Note: Patients receiving low-dose anticoagulation for the purpose of maintaining central venous catheter patency are eligible.
- •Patients who have an inherited or acquired bleeding diathesis, including (but not limited to) hemophilia or immune or thrombotic thrombocytopenic purpura, or who have had an underlying condition that predisposes to abnormal bleeding (e.g., peptic ulcer disease) within 1 year prior to the first dose of ABT-263
- •Patients with a history of refractoriness to platelet transfusions
- •Clinically significant cardiovascular disease
- •Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or RNA
- •Pregnancy or breastfeeding
- •Concurrent (or within 7 days prior to the first dose of study treatment) systemic corticosteroid therapy except some low-dose corticosteroid therapies
- •History of other disease, metabolic dysfunction, physical or laboratory finding(s) giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, might affect interpretation of the results of the study or render the patient at high risk from treatment complications
- •History of anaphylaxis, allergic reaction, or hypersensitivity to sulfites (sodium metabisulphite is included in study drug formulation)
- •Any contraindication to alcohol ingestion (study drug formulation includes approximately 15% ethanol)
研究组 & 干预措施
C
Experimental
干预措施: ABT-263 (Drug)
A
Active Comparator
干预措施: rituximab (Drug)
B
Experimental
干预措施: ABT-263 (Drug)
B
Experimental
干预措施: rituximab (Drug)
C
Experimental
干预措施: rituximab (Drug)
结局指标
主要结局
Progression-free survival
时间窗: From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from First Patient In [FPI])
次要结局
- ORR as assessed by a blinded, independent review(Approximately 40 months from FPI)
- Duration of response as assessed by a blinded, independent review(Approximately 40 months from FPI)
- Overall survival (OS)(From randomization until death due to any cause (approximately 4 years after Last Patient In))
- Duration of response(Approximately 40 months from FPI)
- Overall response rate (ORR)(Approximately 40 months from FPI)
- Complete response (CR) rate(Approximately 40 months from FPI)
- Progression-free survival as assessed by a blinded, independent review(From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from FPI))
- CR rate as assessed by a blinded, independent review(Approximately 40 months from FPI)
研究者
相似试验
已完成
2 期
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerMetastatic Breast CancerNCT02491983MedSIR486
Unknown
2 期
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT04502680The First Affiliated Hospital with Nanjing Medical University100
已完成
2 期
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyNon-small Cell Lung CancerNCT04249362AstraZeneca102
进行中（未招募）
2 期
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraMultiple MyelomaNCT03896737European Myeloma Network B.V.401
已完成
2 期
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)Carcinoma, Merkel CellNCT02155647EMD Serono Research & Development Institute, Inc.204